Evaluating vaccine and other biologic preparations for the presence of host cell contaminants is critical for assuring the quality and safety of these products. The presence of residual host cell DNA in the final product is of concern due to the potential oncogenic properties of the DNA from the immortalized cell line.
In addition to bulk- and final-product release testing, residual DNA is also usually tested on in-process samples to ensure manufacturing consistency and product safety.
Due to the broad spectrum of sample matrices used in these tests, the sample preparation method must function equally well across all matrices with minimal sample manipulation.
This one-hour webinar focuses on optimizing the residual host cell DNA detection workflow to ensure consistent, high-quality results.
Topics for discussion include: